RU97108050A - Способ ингибирования состояний, связанных с нейропептидом y - Google Patents

Способ ингибирования состояний, связанных с нейропептидом y

Info

Publication number
RU97108050A
RU97108050A RU97108050/14A RU97108050A RU97108050A RU 97108050 A RU97108050 A RU 97108050A RU 97108050/14 A RU97108050/14 A RU 97108050/14A RU 97108050 A RU97108050 A RU 97108050A RU 97108050 A RU97108050 A RU 97108050A
Authority
RU
Russia
Prior art keywords
neuropeptide
excess
condition associated
compound
conditions associated
Prior art date
Application number
RU97108050/14A
Other languages
English (en)
Other versions
RU2188015C2 (ru
Inventor
Фредерик Брунс Роберт (младший)
Ричард Гелерт Дональд
Джеффри Хоуберт Джеймс
Генри Уолкер Лунн Уильям
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/326,675 external-priority patent/US6562862B1/en
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of RU97108050A publication Critical patent/RU97108050A/ru
Application granted granted Critical
Publication of RU2188015C2 publication Critical patent/RU2188015C2/ru

Links

Claims (8)

1. Способ ингибирования физиологического расстройства, связанного с избытком нейропептида Y, включающий введение нуждающемуся в этом человеку, эффективного количества соединения формулы 1
Figure 00000001

где R1 и R3 независимо представляют водород, -CH3,
Figure 00000002

где Ar представляет необязательно замещенный фенил;
R2 выбран из группы, состоящей из пирролидино, гексаметиленимино и пиперидино; или его фармацевтически приемлемой соли или сольвата.
2. Способ по п.1, отличающийся тем, что указанное соединение представляет собой его хлористоводородную соль.
3. Способ по п. 1, отличающийся тем, что указанное введение является профилактическим.
4. Способ по п.1, отличающийся тем, что указанное соединение представляет собой
Figure 00000003

или его хлористоводородную соль.
5. Способ по п.1, отличающийся тем, что состоянием, связанным с избытком нейропептида Y, является тревога.
6. Способ по п.1, отличающийся тем, что состоянием, связанным с избытком нейропептида Y, является ожирение.
7. Способ по п.1, отличающийся тем, что состоянием, связанным с избытком нейропептида Y, является депрессия.
8. Способ по п.1, отличающийся тем, что состоянием, связанным с избытком нейропептида Y, является боль или восприятие повреждающих воздействий нервными центрами.
RU97108050/14A 1994-10-20 1995-10-19 Способ ингибирования нейропептида y RU2188015C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/326,675 1994-10-20
US08/326,675 US6562862B1 (en) 1994-10-20 1994-10-20 Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Publications (2)

Publication Number Publication Date
RU97108050A true RU97108050A (ru) 1999-05-10
RU2188015C2 RU2188015C2 (ru) 2002-08-27

Family

ID=23273204

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97108050/14A RU2188015C2 (ru) 1994-10-20 1995-10-19 Способ ингибирования нейропептида y

Country Status (19)

Country Link
US (5) US6562862B1 (ru)
EP (1) EP0785785A4 (ru)
JP (1) JPH10507757A (ru)
KR (1) KR970706818A (ru)
CN (1) CN1091598C (ru)
AU (1) AU689664B2 (ru)
CA (1) CA2200990A1 (ru)
CZ (1) CZ287411B6 (ru)
FI (1) FI971635A0 (ru)
HU (1) HUT76852A (ru)
IL (1) IL115663A (ru)
MY (1) MY132056A (ru)
NO (1) NO971520L (ru)
NZ (1) NZ295575A (ru)
RU (1) RU2188015C2 (ru)
TW (1) TW410156B (ru)
UA (1) UA46744C2 (ru)
WO (1) WO1996012490A1 (ru)
ZA (1) ZA958800B (ru)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5494929A (en) * 1995-01-12 1996-02-27 Eli Lilly And Company Methods of inhibiting growth hormone effects
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
US5532254A (en) * 1995-06-07 1996-07-02 Eli Lilly And Company Modulation of calcium channels using benzothiophenes
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
AU730137B2 (en) 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
US6113876A (en) * 1996-01-29 2000-09-05 Eli Lilly And Company Methods of increasing sphincter competence
JP2000503991A (ja) * 1996-01-29 2000-04-04 イーライ・リリー・アンド・カンパニー 括約筋受容能力を増大させる方法
US6849733B1 (en) 1996-08-23 2005-02-01 Agouron Pharmaceuticals, Inc. Neuropeptide-Y ligands
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
JP2000510164A (ja) * 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
EP0927166A1 (en) * 1997-02-14 1999-07-07 Bayer Corporation Amides as npy5 receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
DE69812096T2 (de) * 1997-04-23 2003-10-30 Banyu Pharma Co Ltd Neuropeptid y rezeptorantagonisten
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
DK0896822T3 (da) * 1997-08-05 2003-06-02 Pfizer Prod Inc 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
ATE296825T1 (de) 1997-08-05 2005-06-15 Pfizer Prod Inc 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
WO1999008523A1 (en) * 1997-08-21 1999-02-25 Eli Lilly And Company Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis
WO1999008526A1 (en) * 1997-08-21 1999-02-25 Eli Lilly And Company Methods for inhibiting temporomandibular disorders
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US20050107327A1 (en) * 1997-12-19 2005-05-19 Hormos Medical Corporation Method for reducing overproduction of neuropeptide Y in an individual
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB2344050A (en) * 1998-11-26 2000-05-31 Ferring Bv Agents useful in the treatment of reproductive disorders.
DK1027891T3 (da) 1999-01-27 2005-05-09 Pfizer Prod Inc Neuropeptid-Y-antagonister
KR20010101931A (ko) 1999-02-03 2001-11-15 피터 지. 스트링거 α1-아드레날린성 수용체 길항제
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000066578A1 (en) 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
JP2003510327A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション 特定のアルキレンジアミンで置換された複素環
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
WO2001053477A1 (en) * 2000-01-20 2001-07-26 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of neuropeptide y activity
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6511984B2 (en) 2000-03-30 2003-01-28 Pfizer Inc. Neuropeptide Y antagonists
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US6949564B2 (en) * 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
US6958347B2 (en) * 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
JP2004224756A (ja) * 2003-01-24 2004-08-12 Sumika Fine Chemicals Co Ltd ２，６−ジハロゲノ−８−置換−プリン化合物およびその製造方法
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
BRPI0507485A (pt) 2004-02-05 2007-07-10 Probiodrug Ag inibidores novos de glutaminil ciclase
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
AU2005237274B2 (en) * 2004-05-04 2011-02-17 Hormos Medical Ltd Novel oral formulations of ospemifene
WO2006050999A2 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
EP1877076A4 (en) * 2005-04-15 2012-02-01 Regenertech Pty Ltd USE OF NEUROPEPTIDES Y (NPY) AND AGONIST OF ANTAGONISTS THEREOF FOR REGENERATING TISSUES
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
ES2590262T3 (es) * 2007-02-14 2016-11-21 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
ES2575131T3 (es) 2007-12-03 2016-06-24 Obe Therapy Biotechnology Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa
DK2475428T3 (en) 2009-09-11 2015-09-28 Probiodrug Ag Heterocyclic derivatives as glutaminylcyklaseinhibitorer
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
US8877801B2 (en) * 2013-02-19 2014-11-04 Novartis Ag Compounds and compositions as selective estrogen receptor degraders
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4891357A (en) * 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
AU672182B2 (en) 1991-11-27 1996-09-26 Novo Nordisk A/S Piperidine derivatives and their use in treating psychosis
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
ES2105525T3 (es) 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
TW303299B (ru) 1993-07-22 1997-04-21 Lilly Co Eli
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5457113A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5574047A (en) 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
ZA9410076B (en) 1993-12-21 1996-06-19 Lilly Co Eli Methods of inhibiting obsessive-compulsive and consumptive disorders
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5439931A (en) 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women

Similar Documents

Publication Publication Date Title
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950010893A (ko) 자궁내막증 억제 방법
RU97114956A (ru) Способ ингибирования межклеточной адгезии и способ ингибирования воспалительного процесса
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
RU98113525A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования тромботического расстройства, для увеличения активации протеина с
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950016729A (ko) 유방 질환의 억제 방법
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
EA199800015A1 (ru) Способ ингибирования меланомы
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
RU97107855A (ru) Способ ингибирования состояний, ассоциированных с брадикинином
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법
KR970706819A (ko) 브라디키닌 관련 증상 억제 방법(Method of Inhibiting Conditions Associated with Bradykinin)
RU97104160A (ru) Способ ингибирования (угнетения) эндометриального рака